Harness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca, Takeda, Corvus Pharmaceuticals, iTeos Pharmaceuticals and more to maximize commercial opportunity of the adenosine-pathway as a second-generation immuno-oncology target.